

Afghanistan

Population 2018

37 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	70 (45–100)	189 (122–270)
HIV-positive TB incidence	0.32 (0.12–0.64)	0.87 (0.31–1.7)
MDR/RR-TB incidence ^{oo}	2.5 (1–4.7)	6.8 (2.8–13)
HIV-negative TB mortality	11 (6.4–16)	29 (17–44)
HIV-positive TB mortality	0.098 (0.036–0.19)	0.26 (0.1–0.52)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	3% (1.4–5.3)
Previously treated cases	12% (11–14)

TB case notifications, 2018

Total new and relapse	48 420
- % tested with rapid diagnostics at time of diagnosis	24%
- % with known HIV status	53%
- % pulmonary	71%
- % bacteriologically confirmed ^{ooo}	64%
- % children aged 0–14 years	21%
- % women	46%
- % men	33%
Total cases notified	48 800

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	69% (48–110)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	16% (8–26)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	7	<1%
- on antiretroviral therapy	3	43%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	49%
- Previously treated cases	95%
Laboratory-confirmed cases*	MDR/RR-TB: 452, XDR-TB: 8
Patients started on treatment**	MDR/RR-TB: 319, XDR-TB: 8
MDR/RR-TB cases tested for resistance to second-line drugs	253

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	91%	46 640
Previously treated cases, excluding relapse, registered in 2017	42%	766
HIV-positive TB cases registered in 2017	29%	7
MDR/RR-TB cases started on second-line treatment in 2016	62%	153
XDR-TB cases started on second-line treatment in 2016		

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	95% (88–100)

TB financing, 2019

National TB budget (US\$ millions)	17
Funding source: 3% domestic, 76% international, 21% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Legend:
■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:
■ Females
■ Males
 Incidence

Treatment success rate (%)



Legend:
■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive
■ MDR/RR-TB
■ XDR-TB

Total budget (US\$ millions)



Legend:
■ Unfunded
■ Funded internationally
■ Funded domestically